Roche to Pay USD 75 Mn Upfront for Global Rights to Simcere's Experimental Blood Cancer Drug
Bengaluru: Switzerland's Roche will pay USD 75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
SIM0660 targets B-cell malignancies, Simcere said in a filing to the Hong Kong stock exchange.B cells are a type of white blood cell that produces antibodies. Simcere is also eligible to receive up to about $1.46 billion in payments for unspecified milestones.
Roche will receive exclusive global rights to develop, manufacture and commercialise SIM0660.
A Simcere spokesperson told Reuters SIM0660 is a preclinical product. Roche did not immediately respond to a request for comment on what specific diseases it intended to study SIM0660 for, or potential clinical trial timelines.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.